LTR Pharma (ASX:LTP) completed the data evaluation phase of its clinical study on SPONTAN, its intranasal formulation of erectile dysfunction medication vardenafil, according to a Monday filing with the Australian Securities Exchange.
The study found that SPONTAN nasal spray had a 470% faster absorption rate than oral tablets and was well-tolerated with no serious adverse events, the filing said.
LTR Pharma shares were down nearly 2% in midday trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments